SCHEMBL6018087

SCHEMBL6018087

CC(O)CNc1ccc(S(=O)(=O)Oc2ccc3[nH]c(N(C)C(=O)O)nc3c2)cc1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 2/20 0.35
ALDH1A1 P00352 4/20 0.33
MEN1 O00255 3/20 0.33
KMT2A Q03164 3/20 0.33
LMNA P02545 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
MAPT P10636 2/20 0.33
PTBP1 P26599 1/20 0.33
MCHR1 Q99705 4/20 0.33
ENPP2 Q13822 2/20 0.32
ENPP1 P22413 3/20 0.32
ENPP3 O14638 2/20 0.32
ABL1 P00519 1/20 0.32
RECQL P46063 1/20 0.31
KDM4E B2RXH2 1/20 0.31
ADAMTS4 O75173 1/20 0.31
HSP90AA1 P07900 1/20 0.31
GAA P10253 1/20 0.31
MAPK1 P28482 1/20 0.31
TDP1 Q9NUW8 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5036815 0.89 ENPP1 (0.35) EGFRALDH1A1MEN1KMT2ALMNA
SCHEMBL5041060 0.87 ACE2 (0.35) EGFRALDH1A1MEN1KMT2ALMNA
SCHEMBL5036765 0.87 MEN1 (0.37) EGFRALDH1A1MEN1KMT2ALMNA
SCHEMBL5041026 0.86 MEN1 (0.37) EGFRALDH1A1MEN1KMT2ALMNA
SCHEMBL6017774 0.86 EGFR (0.35) EGFRALDH1A1MEN1KMT2ALMNA
SCHEMBL5042900 0.86 MET (0.40) ALDH1A1MEN1KMT2ALMNASMN1; SMN2
SCHEMBL5033719 0.86 MAPT (0.35) EGFRALDH1A1MEN1KMT2ALMNA
SCHEMBL5140564 0.85 ACE2 (0.33) EGFRALDH1A1MEN1KMT2ALMNA
SCHEMBL5036159 0.85 ALDH1A1 (0.35) EGFRALDH1A1MEN1KMT2ALMNA
SCHEMBL6017783 0.84 CA1 (0.37) ALDH1A1MEN1KMT2ALMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7041668-B2 Substituted benzimidazole compounds and their use for the treatment of cancer AVENTIS PHARMA S.A. (FR) 2006-05-09 US disclosed
US-20050014811-A1 Substituted benzimidazole compounds and their use for the treatment of cancer AVENTIS PHARMA S.A. (FR) 2005-01-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014811-A1 Substituted benzimidazole compounds and their use for the treatment of cancer CDKL3, CCNL2, CDKL1 EGFR 27/4885ALDH1A1 1134/4885MEN1 3925/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.